Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
R K Pharma
AddedFeb 15, 2024
UpdatedJun 18, 2026
R K Pharma

R K Pharma

RK Pharma: Innovating healthcare with quality pharmaceutical ingredients and generic products.

HQ
Pearl River, NY, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to innovate healthcare, RK Pharma specializes in the development and manufacturing of high-quality pharmaceutical ingredients and generic products. The company aims to address formulation challenges and provide affordable medication options. Their product lineup includes diclofenac potassium tablets, mycophenolic acid DR tablets, and mitomycin injection vials, among others. RK Pharma focuses on the healthcare market, particularly on products that require unique formulation solutions.

RK Pharma has established itself as a significant player in the pharmaceutical industry through its integrated development, regulatory, and manufacturing capabilities. The company collaborates with various drug product partnerships to enhance its market reach. Notable achievements include the successful commercialization of several complex generic medications. By providing cost-effective and high-quality pharmaceutical solutions, RK Pharma has made a substantial impact on improving patient access to essential medications.

R K Pharma - Quick Facts

When was R K Pharma founded?

R K Pharma was founded in 2018.

Where is R K Pharma's headquarters located?

R K Pharma's headquarters is located in Pearl River, NY, US.

When was R K Pharma's last funding round?

R K Pharma's most recent funding round was for $200M (USD) in June 2023.

How much has R K Pharma raised to-date?

As of Jun 6, 2023, R K Pharma has raised a total of $200M (USD).

How many employees does R K Pharma have?

R K Pharma has 1,001 employees as of Feb 4, 2024.

R K Pharma - Classification

Ownership
  • Private
Geographic Exposure
  • Global
Model
  • Manufacturing
Revenue
  • Recurring
  • Software
  • Transactional
Customer
  • Enterprise
Main Product
  • Generics
  • Pharmaceuticals
Tags
  • Healthcare
  • Pharmaceuticals
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
Show 10 more industry codes
NAICS
  • 456000Health and Personal Care Retailers
  • 450000Retail Trade
  • 620000Health Care and Social Assistance
  • 456100Health and Personal Care Retailers
  • 456110Pharmacies and Drug Retailers
SIC
  • 5900Miscellaneous Retail
  • 8000Health Services
  • 5910Drug Stores And Proprietary Stores
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified